Furthermore, diminishing MIF expression within the primary tumor in vivo triggers a robust anti-tumor immune response characterized by enhanced DC maturation, followed by an increase in IFN–gamma-producing T cells within the tumor [166]. The gene discussed is MIF; the disease is neoplasm.